François Miceli is graduated in biological engineering at the University of Paris XII – UPEC, former student of INSEAD (Corporate Finance, EE) and auditor at IHEDN (Institut des Hautes Etudes de Défense Nationale, promotion Chevalier Bayard),
After having been Venture Partner and member of the investment committee, François MICELI fully joined the private equity firm SOFIMAC PARTNERS in 2012 as Senior Partner. Associate Managing Director of SOFIMAC INNOVATION, a management company managing 400 million euros in innovation capital which has just merged with UI Investissement in which François holds the position of Senior Associate Director for Innovation.
François is also a director of Exeliom Biosciences, Ixaltis, Eurekam, Diabeloop, Igyxos, Axoltis, Aptys Pharmaceuticals, Cellmade, Isorg, Precilens and Futuragaia.
He is also a member of the Board of Directors of the M2CARE accelerator specialized in health and nutrition and was President of the SAS INSERM TRANSFERT INITIATIVE.